ALFA Finder| Revenue growth | 13% YoY in FY26; 15% growth guided for FY27. |
|---|---|
| Margins | EBITDA margins improved to 20%; targeting 22% and above. |
| Order book | Significant portion of planned capacity already committed. |
| Demand visibility | Strong; capacity for ibuprofen already 80% utilized. |
| Management confidence | High; citing benefits from backward integration and new capacity. |
Growth
FY26 Revenue increased 13% to ₹887cr; EBITDA grew 23% to ₹171cr with 20% margins.
Outlook
Guiding 15% revenue growth for FY27 with 22% EBITDA margin targets; ₹280cr brownfield capex ongoing.
Risks
Geopolitical tensions in Middle East impacting logistics, freight costs, and solvent prices.
Earnings Call filed with NSE, NSE: SMSPHARMA. Summary written with AI assistance from the document.
SMS Pharmaceuticals Ltd: key numbers
- Share price
- ₹520.90
- Market cap
- ₹4,618 Cr
- Revenue (annual)
- ₹886.9 Cr
- Net profit (annual)
- ₹102.0 Cr
- P/E (TTM)
- 39.5×Sector 43.8×
- Promoter holding
- 68.07%+0.00% QoQ
- FII holding
- 1.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SMS Pharmaceuticals Ltd
All →SMS Pharmaceuticals Results Update
SMS Pharmaceuticals released a press release on its Q2 and H1 FY27 results, showing strong growth. Management now expects FY27 revenue growth and EBITDA margins above earlier guidance.
SMS Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue ₹316 Cr (+30% YoY), EBITDA ₹68 Cr at 21% margin, PAT ₹40 Cr (+57%). Strategy: backward integration, high-value APIs, DMF/CEP filings, ₹280 Cr capex.
SMS Pharmaceuticals Management Change
SMS Pharmaceuticals' Company Secretary Thirumalesh Tumma resigned effective November 4, 2026. Manohar Mollama has been appointed as the new Company Secretary effective November 5, 2026.
SMS Pharmaceuticals Q2 FY27 Results: Net Profit ₹39.9 Cr, Up 57.7% YoY
SMS Pharmaceuticals Ltd reported revenue from operations of ₹316.1 Cr (+30.4% YoY) and net profit of ₹39.9 Cr (+57.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹39.9 Cr · +57.7% YoY
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals received an Income Tax appellate order under Section 250 dismissing its appeal for AY 2018-19. The company says there is no material impact and is reviewing next steps.
- Value
- ₹0.40 Cr
SMS Pharmaceuticals Legal & Regulatory
SMS Pharmaceuticals disclosed that the CIT(Appeals) dismissed its appeal against a ₹7.19 Crore income tax assessment for AY 2018-19. The company is reviewing the order and expects no material impact.
- Value
- ₹7.19 Cr